Targeting G-quadruplexes may restore chemotherapy effectiveness
Category: News
OVX836 shown to be safe and effective alongside seasonal Fluarix Tetra
BX004 achieves 500-fold bacterial reduction with no resistance in phase 1b/2a study
Funding to support lead candidate targeting FAP and pipeline expansion
New trial to test VMX-C001’s effectiveness in restoring coagulation in FXa DOAC patients
Enter the 2025 PharmaTimes Clinical Researcher of the Year – The Americas
PulseSight begins phase 1 safety study of gene therapy for geographic atrophy
SMC approval provides option for postmenopausal women at risk of fractures
CSL Behring marks new era in treatment with milestone reimbursement model